DPP-4 Inhibitors: Oral Glucose-Lowering Medications for Type 2 Diabetes
DPP-4 inhibitors are oral medications that work by blocking the enzyme dipeptidyl peptidase-4, which increases endogenous GLP-1 levels, thereby enhancing insulin secretion and suppressing glucagon secretion in a glucose-dependent manner. 1
Mechanism of Action
DPP-4 inhibitors increase the endogenous level of GLP-1 by reducing its deactivation in vivo through inhibition of the DPP-4 enzyme 2. This mechanism leads to:
- Enhanced insulin secretion in a glucose-dependent manner
- Inhibited glucagon secretion from pancreatic alpha-cells
- Reduced hepatic glucose production
The glucose-dependent nature of their action is critical—they only work when blood glucose is elevated, which explains their low hypoglycemia risk 1.
Available Agents
Commercially available DPP-4 inhibitors include:
- Sitagliptin
- Saxagliptin
- Vildagliptin
- Linagliptin
- Alogliptin 2
Efficacy
DPP-4 inhibitors have moderate glucose-lowering efficacy, reducing HbA1c by 0.4% to 0.9% 2. This places them in the moderate efficacy category compared to other glucose-lowering agents 1.
Safety Profile
Advantages:
- Minimal risk of hypoglycemia when used as monotherapy 2, 1
- Weight neutral effect (no weight gain or loss) 2, 1
- Well tolerated with generally benign adverse event profile 1
Important Caveats:
- When combined with sulfonylureas, hypoglycemia risk increases by 50% compared to sulfonylurea alone 1
- Rare but increased rates of pancreatitis and musculoskeletal side effects have been reported 1
Cardiovascular Safety Considerations
Cardiovascular outcomes trials demonstrated safety but no cardiovascular benefit for sitagliptin, saxagliptin, and alogliptin 2, 1.
Critical warning: Saxagliptin and alogliptin showed imbalances regarding heart failure hospitalizations in clinical trials 1. Saxagliptin specifically increased the risk of heart failure hospitalization by 27% in the SAVOR TIMI-53 trial 3.
Renal Dosing Requirements
Most DPP-4 inhibitors require dose adjustment in renal dysfunction:
- Sitagliptin, saxagliptin, alogliptin, and vildagliptin: dose reduction required based on renal function 2
- Linagliptin is the exception: no dose adjustment needed in liver or renal insufficiency due to minimal renal excretion 2, 1, 2
Clinical Use Restrictions
Do NOT combine DPP-4 inhibitors with GLP-1 receptor agonists (including dual GIP/GLP-1 agonists)—there is no additional glucose lowering beyond that of a GLP-1 RA alone 4. This is wasteful and provides no clinical benefit.
Positioning in Treatment Algorithm
DPP-4 inhibitors are typically used as:
- Second-line therapy after metformin
- Combination therapy with metformin, sulfonylureas, TZDs, or insulin 2
- Alternative to agents with higher hypoglycemia risk in patients where hypoglycemia avoidance is critical
In hospitalized patients with mild-to-moderate hyperglycemia (admission glucose <180 mg/dL), DPP-4 inhibitors combined with low-dose basal insulin have been similarly effective to basal-bolus insulin with less hypoglycemia and less treatment burden 5.